Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1695-1702

  Dobes, Petr ^a   Podhorec, Jan ^a   Coufal, Oldrich ^a   Jureckova, Andrea ^a   Petrakova, Katarina ^a   Vojtesek, Borivoj ^a   Hrstka, Roman ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Breast cancer; Mutation; Prognosis; TP53

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; STOP CODON;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MIDDLE AGED; MISSENSE MUTATION; MUTANT; NONSENSE MUTATION; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SOMATIC MUTATION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WILD TYPE; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; GENETICS; METABOLISM; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; STOP CODON;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CODON, NONSENSE; FEMALE; GENES, P53; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84923068518     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3346     Document Type: Article

References (25)

1. Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R and Abrahámová J: Cancer incidence and mortality in the Czech Republic. Klin Onkol 23: 311-324, 2010.
2. Cancer Research UK. www.cancerresearchuk.org. Accessed march, 2013.
3. Kastan mB, Canman CE and Leonard CJ: P53, cell cycle control and apoptosis: implications for cancer. Cancer metastasis Rev 14: 3-15, 1995.
4. Kastan mB, Onyekwere O, Sidransky D, vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
5. Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233-239, 2001.
6. Greenblatt m, Bennett W, Hollstein m and Harris C: mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
7. Caron de fromentel C and Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1-15, 1992.
8. Brosh R and Rotter v: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713, 2009.
9. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994. (Pubitemid 24259959)
10. Bertheau P, Espié m, Turpin E, et al: TP53 status and response to chemotherapy in breast cancer. Pathobiology 75: 132-139, 2008.
11. Harris CC and Hollstein m: Clinical implications of the p53 tumor-suppressor gene. N Engl J med 329: 1318-1327, 1993.
12. Olivier m, Langerød A, Carrieri P, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167, 2006.
13. Poeta mL, manola J, Goldwasser mA, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J med 357: 2552-2561, 2007.
14. Hrstka R, Beranek m, Klocova K, Nenutil R and vojtesek B: Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep 22: 1205-1211, 2009.
15. Elston C and Ellis I (eds): Assessment of histological grade. In: The Breast. vol 13. Churchill Livingstone, Edinburgh, New York, pp356-384, 1998.
16. Curtis C, Shah SP, Chin Sf, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352, 2012.
17. Geisler S, Lønning PE, Aas T, et al: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001. (Pubitemid 32685830)
18. Chrisanthar R, Knappskog S, Løkkevik E, et al: CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 3: e3062, 2008.
19. Wahl Af, Donaldson KL, faircnild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/m arrest and apoptosis. Nat med 2: 72-79, 1996.
20. Chrisanthar R, Knappskog S, Løkkevik E, et al: Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 6: e19249, 2011.
21. Bonnefoi H, Piccart m, Bogaerts J, et al: TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 12: 527-539, 2011.
22. Geisler S, Børresen-Dale AL, Johnsen H, et al: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9: 5582-5588, 2003. (Pubitemid 37499478)
23. Powell B, Soong R, Iacopetta B, Seshadri R and Smith DR: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6: 443-451, 2000. (Pubitemid 30111462)
24. Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, et al: Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14: R70, 2012.
25. Lai H, ma f, Trapido E, meng L and Lai S: Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat 83: 57-66, 2004. (Pubitemid 38141893)